Soluble complement receptor type 1 inhibits complement activation induced by hemodlalysis membranes in vitro. A variety of bioincompatible events that occur during hemodialysis have been attributed to complement activation. However, cause-effect relationships have been based primarily on indirect evidence and the results of in vitro studies, because an acceptable method for inhibiting complement activation during clinical hemodialysis has been unavailable. Methods for inactivating complement in vitro are available, but the most commonly used of these techniques (heat inactivation and chelation of divalent cations) lack specificity. A recombinant, soluble form of human complement receptor type I (sCR1) has been developed recently and shown to inhibit complement activation in vivo. Here, we report studies aimed at determining the effects of sCR1 on dialysis-induced complement activation and neutrophil degranulation. In a concentration dependent fashion, sCR1 inhibited plasma complement activation by cuprophan membrane in vitro. Using a maximally inhibitory concentration (30 Wml), sCR1 blocked generation of C3a(desArg) by cuprophan, cellulose acetate, and polymethylmethacrylate membranes by 90%, 84%, and 84%, respectively. In contrast, elastase release (a measure of neutrophil degranulation) was inhibited by 70%, 70%, and 44%, respectively, suggesting that dialysis-induced neutrophil activation is mediated in part by noncomplement dependent mechanisms. Both heat-and EDTA-treatment of plasma abolished dialysis membrane-induced complement activation, but these treatments also affected noncomplement dependent components of the degranulation process. These observations show that, compared with other commonly used methods for inhibiting dialysis induced complement activation, 5CR1 is more specific. An additional advantage of sCR1 is its potential for use in the clinical setting.
Soluble complement receptor type 1 inhibits complement activation induced by hemodlalysis membranes in vitro. A variety of bioincompatible events that occur during hemodialysis have been attributed to complement activation. However, cause-effect relationships have been based primarily on indirect evidence and the results of in vitro studies, because an acceptable method for inhibiting complement activation during clinical hemodialysis has been unavailable. Methods for inactivating complement in vitro are available, but the most commonly used of these techniques (heat inactivation and chelation of divalent cations) lack specificity. A recombinant, soluble form of human complement receptor type I (sCR1) has been developed recently and shown to inhibit complement activation in vivo. Here, we report studies aimed at determining the effects of sCR1 on dialysis-induced complement activation and neutrophil degranulation. In a concentration dependent fashion, sCR1 inhibited plasma complement activation by cuprophan membrane in vitro. Using a maximally inhibitory concentration (30 Wml) , sCR1 blocked generation of C3a(desArg) by cuprophan, cellulose acetate, and polymethylmethacrylate membranes by 90%, 84%, and 84%, respectively. In contrast, elastase release (a measure of neutrophil degranulation) was inhibited by 70%, 70%, and 44%, respectively, suggesting that dialysis-induced neutrophil activation is mediated in part by noncomplement dependent mechanisms. Both heat-and EDTA-treatment of plasma abolished dialysis membrane-induced complement activation, but these treatments also affected noncomplement dependent components of the degranulation process. These observations show that, compared with other commonly used methods for inhibiting dialysis induced complement activation, 5CR1 is more specific. An additional advantage of sCR1 is its potential for use in the clinical setting.
During hemodialysis, plasma complement is activated by the dialysis membrane. The complement system is the primary effector of humoral immunity, and activation of the complement cascade generates a variety of proinfiammatory events [1, 2] . Complement activation can mediate cellular injury directly through generation of the potentially cytolytic membrane attack complex (C5b-9); however, most of the proinfiammatory events associated with complement activation are mediated by stimulation of cellular constituents of the immune system through interactions with specific membrane receptors that bind complement activation products [3, 4] . Many of the untoward consequences of hemodialysis have been attributed to membraneinduced activation of complement. Evidence in support of a In vitro methods for inhibiting complement activation are available. The most commonly used of these methods are heat inactivation [9] , chelation of divalent cations with EDTA [9, 10] , and the use of plasma with an isolated deficiency of a particular complement component [11] . Heat treatment of plasma blocks complement activation by destroying the functional activity of heat labile components of both the classical (primarily C2) [12] and the alternative (primarily factor B) [13] pathways. Both pathways also require divalent cations (the classical pathway requires both calcium and magnesium, while the alternative pathway is magnesium dependent) [1, 2] . Thus, treatment of plasma with EDTA also inhibits activation of both the classical and alternative pathways. Heat treatment and chelation of divalent cations are simple and effective methods for abolishing complement activity, but both methods lack specificity. For example, heating plasma for 30 minutes at 56°C may affect the function of noncomplement proteins, and EDTA will affect any process that is divalent cation dependent. The lack of specificity is particularly problematic in experiments that analyze effects that are not entirely complement dependent or are mediated indirectly by complement activation. For example, cuprophan membraneinduced neutrophil degranulation has been shown to be mediated by both complement-and noncomplement-dependent mechanisms [11] . Further, adhesion of cells to cuprophan membraneassociated plasma proteins is an essential component of the neutrophil degranulation process. Inasmuch as this binding is divalent cation dependent [11, 14, 15] , treatment of plasma with EDTA prevents not only complement activation but also neutrophil adhesion. Thus, in this setting, it is impossible to determine if a noncomplement plasma constituent contributes to the degranulation process.
Because of its specificity, plasma with an isolated deficiency of a particular complement component (such as C3-deficient plasma) is useful for analyzing the effects of complement activation [11] . Interpretation of results is usually unambiguous if an effect that is lost when the deficient plasma is used is restored when the deficient plasma is repleted with the missing complement protein. A major disadvantage of complement deficient plasma is the lack of simplicity in the preparation and characterization of the reagent. Further, complement deficient plasma cannot be used to assess the effects of complement activation during clinical dialysis. Complement receptor type I (CR1, CD35) is a 210 to 330 kDa (depending on the allotype) type I integral membrane protein that is present on erythrocytes, leukocytes, and on some nonhematopoietic tissues [3, 16, 17] . CR1 has distinct binding sites for both C3b and C4b, and erythrocyte CR1 appears to play a critically important role in the metabolism of immune complexes. CR1 regulates complement activation in two ways. First, it has decay accelerating activity for the C3 and C5 convertases of both the classical and the alternative pathways. Second, it serves as a cofactor for the enzymatic degradation of C3b and C4b by factor I. Unlike the activity of factor H, the plasma protein that regulates the C3 and C5 convertases of the alternative pathway, the activity of CR1 is not restricted on alternative pathway activator surfaces [18] . This property of CR1 is of critical importance in the present studies, because dialysis membranes are alternative pathway activators [5, 6, 19] . A recombinant, soluble form of complement receptor type 1 (5CR1) has become available recently [18, 20] . sCR1 is a truncated form of the membrane-associated protein that lacks the hydrophobic transmembrane domain, making the recombinant protein soluble in aqueous solutions.
Because of its specificity and its potential for use in the clinical setting, sCR1 appears to be an ideal reagent for use in experiments aimed at delineating the role of complement in bioincompatible events associated with hemodialysis. As a first step toward accomplishing these aims, the effects of sCR1 on complement activation by dialysis membrane in vitro were analyzed.
Methods

Reagents
The following buffers and reagents were used: phosphate buffered saline (PBS) contained 10 m sodium phosphate, pH 7.4 and 145 mM NaCl; HBSSIA, Hank's balanced saline solution containing 0.5% (wt/vol) human serum albumin (Albuminar®, Armour Pharmaceutical, Kankakee, Illinois, USA); disodium ethylenediamine tetraacetate (EDTA; Sigma Chemical Co., St. Louis, Missouri, USA); sodium heparin (LyphoMed, Rosemont, Illinois, USA). sCR1 (BRL55730) was a kind gift of Dr. James Levin (T Cell Sciences, Inc., Cambridge, Massachusetts, USA).
Plasma preparation and neutrophil isolation
Whole blood from healthy volunteers who had not taken medication within 72 hours of the phlebotomy was anticoagulated using 2 units of heparin/mI. Normal human plasma (NHP) was prepared by centrifuging a portion of the blood and recovering the supernate. For some experiments, EDTA (10 m final concentration) was added to the plasma to chelate plasma divalent cations (EDTA-treated plasma) [9, 10] . In some instances, the plasma was heated for 30 minutes at 56°C to inactivate complement (heat-treated plasma) [9, 12, 13] . Heat-treated plasma was centrifuged at 12,000 g for three minutes prior to use. All plasma was diluted to 75% (vol/vol) with PBS and kept at 4°C prior to use on the same day.
Additional heparin (5.5 U/mI) was added to the portion of blood that was not used in the preparation of the plasma.
Neutrophils were isolated by dextran sedimentation, hypotonic lysis of erythrocytes, and density gradient centrifugation (FicollPaque®, Pharmacia LKB Biotechnology, Piscataway, New Jersey, USA) as previously described [21] and were resuspended in HBSS/A. The cell preparations were >95% pure as determined by microscopic examination of slides stained with Wright's reagent, and the cells were 99% viable as determined by tiypan blue exclusion.
Plasma and neutrophils from a number of different donors were used in these studies. On a given day, however, the same donor's cells and autologous plasma were used in all parallel experiments.
Hemodialysis membranes
The following three different types of commercial hemodialysis membranes in hollow fiber format were used in these studies:
cuprophan (CF1211, Travenol, Deerfield, Illinois, USA), cellulose acetate (CA; CA9O, Baxter, Round Lake, Illinois, USA), and polymethylmethacrylate (PMMA; Filtryzer B1-2.1U, Toray Industries, Tokyo, Japan). The membranes were cut into fragments of -1 cm in length, and 4.7 mg of fibers were used in each individual assay. Although the weight of the fibers were the same, the actual surface area that was available for contact with the cells and plasma might vary from one type of membrane to another because of the asymmetric nature of some membranes and the differences in their densities. Therefore, comparison of results among the different types of membranes is inappropriate.
Concentration-dependent inhibition of complement activation
by sCR1
An aliquot of 125 pi of heparinized normal human plasma (NHP) was incubated at 37°C with 4.7 mg of cuprophan membrane and 3.3 X 10 neutrophils in the presence of either PBS or PBS containing incremental concentrations of sCR1. The total volume of the reaction mixture was 250 i.tl. After 120 minutes, 90
.d of the supernate was recovered, and an equal volume of complement stablizing solution (Quidel, San Diego, California, USA) and 4.5 id of 200 mtvi EDTA were added. The plasma samples were stored at -70°C prior to being assayed for complement activation products as described below.
Effect of sCR1 on complement activation and neutrophil degranulation induced by dialysis membranes NHP (125 1.d) was incubated with 4.7 mg of cuprophan, CA, or PMMA membranes and 3.3 x io isolated neutrophils in the presence of either PBS or PBS containing 30 WmI of sCR1. The total volume of the reaction mixture was 250 pA. In parallel experiments, either heat-or EDTA-treated plasma was substituted for NHP, and the samples were incubated with neutrophils and PBS (without sCR1) as described above. For each type of plasma, an aliquot was treated with complement stablizing solution and EDTA as described above and immediately stored at -70°C without incubation. These control samples were used to determine the basal C3a(desg) concentrations in the plasma. After 120 minutes, the supernate was recovered from the other tubes and complement stablizing solution and EDTA were then added. All plasma samples were stored at -70°C prior to being assayed for C3a(de$g) and the neutrophil granular proteins, elastase and lactoferrin (see below). The increase in the concentration of C3a(des.g) was calculated by subtracting the basal concentration from that of the test samples.
Assays for complement activation Complement activation was assessed by measuring the concentration of C3a(desArg) in the supernate using a radioimmunoassay (RIA) kit purchased from Amersham (Arlington Heights, Illinois, USA). The standard curve for this assay is linear between 20 to 500 ng/ml. Generation of the membrane attack complex of complement was determined by quantitating SC5b-9 using an enzyme immunoassay (EIA) purchased from Quidel (San Diego, California, USA). The standard curve is linear between 0 to 142 ng/ml.
ELISA for elastase and lactofemn
Elastase and lactoferrin were used as markers of release of primaly and secondary neutrophil granules, respectively. Elastase was measured using a two site enzyme-linked immunosorbent assay (ELISA) as previously described [11] . The standard curve for this assay is linear between 6 to 100 ng/ml. Lactoferrin was measured using the same type of ELISA developed in our laboratory. The IgG fraction of rabbit anti-human lactoferrin (Sigma Chemical Co, St. Louis, Missouri, USA) was used as the capture antibody, and the peroxidase-conjugated [22] IgG fraction of anti-human lactoferrin (Cappel, Malvern, Pennsylvania, USA) was used as the developing antibody. Human lactoferrin (Sigma) was used to prepare the standards. The standard curve that was developed was linear between 4 to 125 ng/ml of lactoferrin.
Data presentation and statistical analyses
All values are reported as the mean SEM. Differences in concentrations of C3a(desg), elastase, and lactoferrin among the four experimental groups in Figures 2 to 4 were first evaluated using analysis of variance (ANOVA). Since there were statistically significant differences (P < 0.001) among the groups as determined by ANOVA, Student's unpaired two-tailed t-test was used to further analyze differences between groups [23] .
Results
Inhibition of complement activation associated with cuprophan membrane by sCR1 NHP was incubated with cuprophan membrane and neutrophils in the presence of incremental concentrations of sCR1. Maximum inhibition of C3 occurred at 30 tg/ml when generation of the C3a(desArg) was reduced by -P90% (Fig. 1A) . Maximum inhibition of SC5b-9 required a lower concentration of sCR1. At 10 g/ml of sCR1, no SC5b-9 could be detected in the plasma (Fig. 1B) . These results showed that sCR1 is effective in inhibiting complement activation induced by dialysis membranes.
Effect of sCR1, heat-inactivation, and EDTA-treatment on complement activation and neutrophil degranulation induced by various types of dialysis membranes
The effects of sCR1 on complement activation and neutrophil degranulation associated with various types of dialysis membranes were assessed individually. Since both C3 and the terminal components appeared to be maximally inhibited by 30 j.tg/ml of sCR1 ( Fig. 1 A and B) , this concentration was used in all sCR1, pg/mi tg/ml of sCR1, Inhibition at 30 ig/ml (N = 8) was greater than that occurring at 10 jg/ml (N = 7; P < 0.001). Complete inhibition of formation of the SC5b-9 complex occurred at 10 g/ml.
subsequent experiments. The effects of heat-and EDTA-treated plasma on dialysis membrane-induced complement activation and neutrophil degranulation were used for comparison with plasma treated with sCR1.
Cuprophan membrane sCR1 inhibited C3a(deg.g) generation associated with cuprophan membrane by 90% (Fig. 2A) . These results are similar to those presented in Figure IA . By comparison, EDTA inhibited C3a(desg) generation by 95%, whereas heat treatment virtually abolished C3 activation ( Fig. 2A) . When neutrophils were incubated with cuprophan membrane and NHP containing sCR1, elastase levels were reduced by 70% (Fig. 2B) . Heat-treatment of plasma produced a similar degree (64%) of inhibition of neutrophil degranulation compared with sCR1 (P > 0.05). sCR1 and heat-treatment decreased lactoferrin levels by 47% and 40%, respectively (P> 0.05, sCR1 vs. heat-treatment; Fig. 2C ). Increasing the concentration of sCR1 to 70 .tgfml or 100 ig/ml did not produce greater inhibition of the release of elastase and lactoferrin compared to 30 .tg/m1 (data not shown). These studies show that sCR1 and heat-treatment were less effective in inhibiting elastase release from neutrophils than in inhibiting complement activation and suggest that a noncomplement dependent pathway participates in the degranulation process. Treatment of plasma with EDTA nearly abolished the release of both elastase and lactoferrin ( Fig. 2 B and C) . These results indicate that both the complement and noncomplement pathways of degranulation are divalent cation dependent.
CA membrane sCR1 inhibited complement activation induced by cellulose acetate by 84%, whereas heat-treatment virtually abolished complement activation, and EDTA reduced generation of C3a(desArg)by 93% (Fig. 3A) . In the presence of sCR1, CAinduced release of neutrophil elastase and lactoferrin were reduced by 70% and 67%, respectively ( Fig. 3 B and C) . In contrast, heat-treatment reduced elastase and lactoferrin release by only 35% and 18%, respectively ( Fig. 3 B and C) . Release of elastase and lactoferrin in the presence of heat-treated plasma was 2-and 2.5-fold greater than the release observed with sCR1-treated plasma (P < 0.02 for elastase and P < 0.001 for lactoferrin, heat-inactivated plasma vs. sCR1). These results suggest that, when CA membranes are used, the activity of the noncomplement dependent pathway of neutrophil degranulation is enhanced by heat-treatment. As was the case with cuprophan membrane (Fig.  2 B and C) , CA-induced neutrophil degranulation was blocked by EDTA ( Fig. 3 B and C) , confirming that both the complementdependent and the heat-stable pathways of degranulation require divalent cations. Fig. 2 . Inhibition of complement activation and neutrophil degranulation induced by cuprophan membrane. Isolated neutrophils were incubated with normal human plasma (NHP) and cuprophan membrane (Cu) in the absence (NHP + Cu) or presence of 30 sg/ml of sCR1 (NHP + Cu ÷ sCR1). Subsequently, the supernate was assayed for C3a(deJg), elastase, and lactoferrin. In parallel experiments, cells were incubated with heatinactivated plasma and cuprophan membrane (HIP + Cu), or with plasma and cuprophan membrane in the presence of 10 mM EDTA (NHP + Cu + EDTA) (N = 9 for each group). Data are presented as mean SCM. (A) Inhibition of C3 activation. sCR1 and EDTA inhibited C3a(desAr generation by 90% and 95%, respectively. Heat-treatment virtually abolished C3 activation. * P < 0.001 vs. NHP + Cu; P< 0.001 vs. NHP + Cu + sCR1.
PMMA membrane
(B) Inhibition of elastase release. sCR1 and heat-treatment inhibited elastase release by 70% and 64%, respectively, suggesting that 30 to 35% of the release from primaly granules is mediated by mechanisms independent of complement activation. EDTA nearly abolished elastase release, indicating that both the complement and noncomplement mechanisms are dependent on divalent cations. * P < 0.001 vs. NHP + Cu; ÷ P < 0.05 or lower vs. NHP + Cu + sCR1. (C) Inhibition of lactoferrin release. sCR1 and heat-treatment reduced the concentration of lactoferrin (a measure of the release from secondary granules) by 47% and 40%, respectively, whereas EDTA virtually abolished lactoferrin release. These observations support the hypothesis that a significant portion of the neutrophil degranulation induced by Cu and NHP is mediated by a complement independent pathway that is divalent cation dependent. * P < 0.002 or lower vs. NHP + Cu; + P < 0.05 or lower vs. NHP + Cu + sCR1. sCR1 also inhibited C3 activation induced by PMMA membrane. The concentration of C3a(desArg) was reduced by 84% in plasma containing sCR1 (Fig. 4A) . Heat-and EDTA-treatment were also effective inhibitors of complement activation induced by PMMA (91% and 94% reduction in plasma C3a(desArg) generation, respectively; Fig. 4A ). In contrast, sCR1 reduced plasma elastase and lactoferrin concentrations by only 44% and 25%, respectively, compared to plasma without sCR1 (these differences were statistically significant, P < 0.005 and P < 0.05, respectively; Fig. 4 B and C) . These results demonstrate that, in contrast to cuprophan, most of the neutrophil degranulation induced by PMMA is mediated by a complement independent pathway. As was the case for cellulose acetate (Fig. 3 B and C) , heat-treated plasma induced greater release of neutrophil granular proteins than sCR1-treated plasma (P < 0.05 for both elastase and lactoferrin, sCR1 vs. heat-treated plasma; Fig. 4 B and C) . These results suggest that the activity of the complement independent pathway of neutrophil degranulation in the presence of PMMA is also enhanced by heat-treatment. Both the complement and noncomplement pathways of degranulation were blocked by EDTA (Fig. 4 B and C) . only 25%, confirming that PMMA induced lactoferrin release from neutrophils is primarily mediated by noncomplement-dependent mechanisms. The decrement in lactoferrin release induced by heat treatment (8%) was significantly less than that produced by sCR1, confirming that the complement-independent pathway that mediates the release from secondary granules is also augmented by heating plasma. Lactoferrin release was reduced by 83% in the presence of EDTA. * P <0.05or lower vs. NH? + PMMA;
+ P < 0.05 or lower vs. NHP + PMMA + sCR1.
Discussion
The purpose of these studies was to determine the capacity of sCR1 to inhibit complement activation induced by various hemodialysis membranes. The results have shown that for cuprophan, CA, and PMMA membranes, sCR1 reduced C3a generation by 90%, 84%, and 84%, respectively (Figs. 1A, 2A, 3A, 4A) .
Cellulosic membranes activate complement via the alternative pathway [5, 6, 19] . The physiological regulator of the alternative pathway is the plasma protein, factor H. Factor H functions by inhibiting the formation and accelerating the decay of the alternative pathway C3 convertase (C3bBb) [24, 25] . Surfaces that activate the alternative pathway are distinguished from nonactivator surfaces, because on activator surfaces, bound C3b has a higher affinity for factor B than for factor H [26, 271 . Under these conditions, the formation and stability of the amplification convertase, C3bBb, are favored. The biochemical properties of a surface that determine its relative affinities for factor B and factor H are incompletely understood; however, the carbohydrate moiety appears to be an important factor [26] [27] [28] [29] . Our previous studies have demonstrated that cellulosic membranes have the properties of an activator surface [19, 30, 31] . CR1 has the same functional profile as factor H, but unlike factor H, the activity of CR1 is not restricted on activator surfaces [18] . Based on these observations, we hypothesized that sCR1 would inhibit complement activation induced by hemodialysis membranes. Maximum inhibition of C3 activation on the three types of membrane ranged from 84 to 90%. The lack of complete inhibition of C3 activation suggests that a portion of the membrane bound C3b (the nonenzymatic subunit of the alternative pathway C3 convertase) may not be accessible to sCR1. Nonetheless, sCR1 is an effective inhibitor of dialysis membrane-induced complement activation. sCR1 completely inhibited generation of the membrane attack complex (Fig. 1B) . Quantitation of SC5b-9 is a surrogate for assessing CS activation. Because of stoichiometric requirements, formation of a functional C5 convertase (C3bBbC3b) is less efficient than formation of a functional C3 convertase (C3bBb) [32}. Thus, the observation that sCR1 more effectively inhibits CS activation than C3 activation (Fig. lB compared to 1A ) was anticipated.
Despite the effectiveness of sCR1 and heat-treatment in inhibiting C3 activation on cuprophan, elastase release was reduced by only 64 to 70% (Fig. 2B ). This degree of inhibition of elastase release (a measure of release of the contents of the primary granules) is similar to that observed in our previous study in which substitution of normal plasma with C3-depleted plasma caused a 62% reduction in elastase release [11] . These results are consistent with the hypothesis that dialysis membrane-induced neutrophil degranulation is mediated by both complement-dependent and complement-independent mechanisms.
Both sCR1 and heat-treatment were less effective in reducing lactoferrin release (a measure of release of the contents of the secondary granules) than in reducing elastase release (Fig. 2C  compared to 2B ). These results suggest that, while secretion of secondary granules is also mediated by both complement-dependent and complement-independent mechanisms, the noncomplement mechanism is dominant. Consistent with this interpretation are studies reporting that release of primary and secondary granules is regulated by different mechanisms [33] .
When cuprophan was used, the effects of sCR1 and heattreatment on neutrophil degranulation were similar (Fig. 2 B and  C) . Based on these observations, it would seem reasonable to conclude that heat-treatment of plasma is a simple and effective way of determining the role of complement in neutrophil degranulation induced by dialysis membranes. The effects of heattreatment of plasma on degranulation induced by CA (Fig. 3 B and C) and PMMA (Fig. 4 B and C) , however, invalidate this conclusion. In contrast to cuprophan, degranulation induced by heat-treated plasma in the presence of CA and PMMA was significantly greater than that observed with sCR1. This difference was almost 2.5-fold in the case of lactoferrin release induced by CA (Fig. 3C) . The addition of sCR1 to heat-treated plasma and neutrophils did not decrease the release of elastase and lactoferrin, compared to incubation of cells with heat-treated plasma alone (data not shown), confirming that the complement-dependent component of neutrophil degranulation had been effectively abolished by heat-treatment of plasma. Together, these data suggest that heating plasma enhances the activity of the noncomplement pathway of degranulation in the presence of these membranes. Inasmuch as the plasma factor(s) involved in the complement-independent pathway has not been identified, the mechanism by which heat-treatment enhances the degranulation process remains speculative.
Clinical hemodialysis using PMMA membrane is associated with higher plasma elastase levels than dialysis using cuprophan membrane even though PMMA induces less complement activation [34, 35] . The explanation for this observation has not been apparent, however, Schaefer, Heidland and HOrl [36] have postulated that shearing of the cells at the blood-dialysis membrane interphase contributes to the degranulation induced by PMMA. Our present studies showed that inhibition of complement activation by PMMA membrane using sCR1 produced only a 44% reduction in elastase release (Fig. 4B) , and inhibition of lactoferrin was even less (25%, Fig. 4C ). These results show that neutrophil degranulation induced by PMMA is mediated primarily by a complement-independent mechanism. Thus, our experiments suggest a plausible explanation for why the plasma elastase levels are high during clinical dialysis using PMMA despite the relatively low complement activation.
Treatment of plasma with EDTA is a simple, effective method of inhibiting complement activation; however, our studies demonstrate that chelation of divalent cations affects processes other than complement activation. Neutrophil degranulation induced by cuprophan membrane is dependent on adhesion of the cells to the membrane. This process is mediated primarily by the f32-integrin, CD11b/CD18 [11] , and adhesion of CD11b/CD18 to its ligands (both complement and noncomplement proteins) is divalent cation dependent [14, 15] . Thus, EDTA inhibits neutrophil degranulation independent of its effect on complement activation (Figs. 2, 3 , and 4), and is therefore not a satisfactory method of assessing the consequences of complement activation.
By making comparisons among various experimental groups using the same type of membrane, we were able to analyze the effects sCR1, and heat-and EDTA-treatment on complement activation and neutrophil degranulation by each membrane. Comparisons of complement activation and neutrophil degranulation among the different types of membranes is problematic, since the actual surface area of the membranes available for contact with plasma and cells may be very different. In this system, in which hollow fiber fragments were used to maximize the surface area, both the blood side and the dialysate side of the membrane were exposed. Asymmetry makes determination of the actual total surface area of the membrane difficult [37] . Additionally, the membranes were standardized by weight (4.7mg in each tube) but not by nominal or actual surface area. Thus, comparisons of complement activation and neutrophil degranulation among the different membranes should be avoided.
In addition to granular proteins, reactive oxygen species are released from neutrophils during hemodialysis [38] . In cooperation with granular proteases or by itself, reactive oxygen species can injure surrounding proteins [39] . Modification of plasma lipids suggestive of free radical activity has also been reported during clinical dialysis [40] . While activated complement fragments, such as C5a [41] and C3b/iC3b [42] , have been shown to induce oxidative burst by neutrophils in vitro, to which extent complement activation contributes to this event during clinical dialysis remains to be determined.
These studies have demonstrated that sCR1 is an effective, specific inhibitor of complement activation induced by dialysis membranes. Considerable resources have been used in an attempt to improve dialysis membrane biocompatibility by reducing the complement activating potential. Direct evidence showing that reduction of complement activation is clinically beneficial, however, is lacking. Our studies support the hypothesis that sCR1 can be used to evaluate the consequences of complement activation during clinical hemodialysis.
